The American Journal of Managed Care: The Questions Are Just Beginning as Smoldering Myeloma Enters a New Era: Peter Voorhees, MD The FDA approval of daratumumab and hyaluronidase-fihj for high-risk smoldering MM shifts care beyond watchful waiting, notes Peter Voorhees, MD. AQUILA enrolled 390 high-risk patients randomized 1:1 ... The Questions Are Just Beginning as Smoldering Myeloma Enters a New Era: Peter Voorhees, MD The Union Democrat: Smoldering multiple myeloma: What it is, how it progresses and the latest research Smoldering multiple myeloma: What it is, how it progresses and the latest research Please provide your email address to receive an email when new articles are posted on .
Daratumumab delayed progression of smoldering multiple myeloma compared with active monitoring. Among those who ... Medical Xpress on MSN: Open-access predictive tool could improve monitoring of smoldering multiple myeloma Dana-Farber Cancer Institute investigators have developed an online, easy-to-use tool that more accurately predicts when a precursor blood condition called smoldering multiple myeloma is likely to ... The FDA on Thursday approved daratumumab-hyaluronidase (Darzalex Faspro) as the first drug for high-risk smoldering multiple myeloma.
smoldering mm, Approval of the subcutaneous daratumumab product was based on ... Nasdaq: DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma The FDA has approved daratumumab and hyaluronidase (DARA SC; Darzalex Faspro, Janssen Biotech) for adults with high-risk smoldering multiple myeloma (SMM). The approval makes DARA SC, a subcutaneous ...
smoldering mm, Cure Today: Darzalex Faspro May Improve Progression, Survival in Smoldering Multiple Myeloma Darzalex Faspro improved PFS and OS in high-risk smoldering multiple myeloma, reducing progression or death risk by 51% and death risk by 48%. The AQUILA study showed a superior overall response rate ... ascopubs.org: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Diagnosis involves blood, urine, and bone marrow tests, with ...
